Abstract
The past decade has seen many exciting achievements and advances in the treatment of HIV infection. One of the key components in this ever-evolving remedial strategy has been medicinally efficacious enzymatic inhibitors targeting the essential viral aspartyl protease. While the use of currently approved HIV protease inhibitors in concert with drugs that target the reverse transcriptase has dramatically ameliorated the disease state for many individuals, highly-structured dosing regimens accompanied by adverse side-effect profiles have led to a significant level of patient non-compliance. In addition, the development of and selection for resistant mutants have limited the long-term therapeutic outlook of the current protease inhibitors. The need for complementary agents in this salutary class addressing these challenges and opportunities is vividly clear. To this end, much attention and focus has been placed on cyclic, non-peptidic protease inhibitors, exemplified by dihydropyrones and ureas, and their possible future role in this medicinal campaign. The strategies to their design as well as their biological, pharmacokinetic and resistance profiles, and their clinical application will be discussed.
Keywords: aids, cyclic urea, dihydropyrone, hiv, non-peptidic protease inhibitor, protease inhibitor
Current Topics in Medicinal Chemistry
Title: Non-Peptidic HIV Protease Inhibitors
Volume: 4 Issue: 10
Author(s): R. Alan Chrusciel and Joseph W. Strohbach
Affiliation:
Keywords: aids, cyclic urea, dihydropyrone, hiv, non-peptidic protease inhibitor, protease inhibitor
Abstract: The past decade has seen many exciting achievements and advances in the treatment of HIV infection. One of the key components in this ever-evolving remedial strategy has been medicinally efficacious enzymatic inhibitors targeting the essential viral aspartyl protease. While the use of currently approved HIV protease inhibitors in concert with drugs that target the reverse transcriptase has dramatically ameliorated the disease state for many individuals, highly-structured dosing regimens accompanied by adverse side-effect profiles have led to a significant level of patient non-compliance. In addition, the development of and selection for resistant mutants have limited the long-term therapeutic outlook of the current protease inhibitors. The need for complementary agents in this salutary class addressing these challenges and opportunities is vividly clear. To this end, much attention and focus has been placed on cyclic, non-peptidic protease inhibitors, exemplified by dihydropyrones and ureas, and their possible future role in this medicinal campaign. The strategies to their design as well as their biological, pharmacokinetic and resistance profiles, and their clinical application will be discussed.
Export Options
About this article
Cite this article as:
Chrusciel Alan R. and Strohbach W. Joseph, Non-Peptidic HIV Protease Inhibitors, Current Topics in Medicinal Chemistry 2004; 4 (10) . https://dx.doi.org/10.2174/1568026043388312
DOI https://dx.doi.org/10.2174/1568026043388312 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
Chemistry Based on Natural Products for Therapeutic Purposes
The development of new pharmaceuticals for a wide range of medical conditions has long relied on the identification of promising natural products (NPs). There are over sixty percent of cancer, infectious illness, and CNS disease medications that include an NP pharmacophore, according to the Food and Drug Administration. Since NP ...read more
Current Trends in Drug Discovery Based on Artificial Intelligence and Computer-Aided Drug Design
Drug development discovery has faced several challenges over the years. In fact, the evolution of classical approaches to modern methods using computational methods, or Computer-Aided Drug Design (CADD), has shown promising and essential results in any drug discovery campaign. Among these methods, molecular docking is one of the most notable ...read more
Drug Discovery in the Age of Artificial Intelligence
In the age of artificial intelligence (AI), we have witnessed a significant boom in AI techniques for drug discovery. AI techniques are increasingly integrated and accelerating the drug discovery process. These developments have not only attracted the attention of academia and industry but also raised important questions regarding the selection ...read more
From Biodiversity to Chemical Diversity: Focus of Flavonoids
Flavonoids are the largest group of polyphenols, plant secondary metabolites arising from the essential aromatic amino acid phenylalanine (or more rarely from tyrosine) via the phenylpropanoid pathway. The flavan nucleus is the basic 15-carbon skeleton of flavonoids (C6-C3-C6), which consists of two phenyl rings (A and B) and a heterocyclic ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
PDE10A Inhibitors: Novel Therapeutic Drugs for Schizophrenia
Current Pharmaceutical Design Molecular Mechanisms, Biological Actions, and Neuropharmacology of the Growth-Associated Protein GAP-43
Current Neuropharmacology Targeted Gene Repair: The Ups and Downs of a Promising Gene Therapy Approach
Current Gene Therapy Targeting Histone Deacetylases for the Treatment of Immune, Endocrine & Metabolic Disorders
Endocrine, Metabolic & Immune Disorders - Drug Targets Potential Role of IL-18 in the Immunopathogenesis of AIDS, HIVAssociated Lipodystrophy and Related Clinical Conditions
Current HIV Research Marfan Syndrome and Related Heritable Thoracic Aortic Aneurysms and Dissections
Current Pharmaceutical Design Epigenetic Control of MicroRNA Expression and Aging
Current Genomics Autism - A Comprehensive Array of Prominent Signs and Symptoms
Current Pharmaceutical Design Therapeutic Advances in the Treatment of Alzheimer's Disease: Present and Future
Current Drug Therapy Thrombotic Thrombocytopenic Purpura, from the Perspectives of a Pediatrician
Current Pediatric Reviews Ubiquitin-Protein Ligases - Novel Therapeutic Targets?
Current Protein & Peptide Science Transcriptomics Study of Neurodegenerative Disease: Emphasis on Synaptic Dysfunction Mechanism in Alzheimer's Disease
CNS & Neurological Disorders - Drug Targets Food Addiction and Neuroimaging
Current Pharmaceutical Design Apoptosis-related BCL2-family Members: Key Players in Chemotherapy
Anti-Cancer Agents in Medicinal Chemistry Genetic Engineering of Allergens for Immunotherapy
Inflammation & Allergy - Drug Targets (Discontinued) Alternatives to Conventional Vaccines - Mediators of Innate Immunity
Current Drug Targets Aerobic Exercise for Preventing Osteoporosis in Postmenopausal Women: an Update of its Effect on Bone Mineral Density
Current Rheumatology Reviews A Systems Biology Perspective on Rational Design of Peptide Vaccine Against Virus Infections
Current Topics in Medicinal Chemistry Cubilin, the Intrinsic Factor-Vitamin B12 Receptor in Development and Disease
Current Medicinal Chemistry Intestinal Barrier Dysfunction in Human Pathology and Aging
Current Pharmaceutical Design